KRAS and neoplasm: In addition, the combined inhibition of the Hippo pathways has been shown to improve the response of tumours to treatment with KRAS G12C-specific inhibitors [88,89], suggesting significant therapeutic potential in cancer treatment and the integration of miRNAs that not only indirectly regulate KRAS, but also all those genes that regulate and are regulated by KRAS.